ABEC launches ATB-2100 bioreactor for advanced therapy manufacturing
ABEC has introduced the ATB-2100 single-use bioreactor, a platform designed to streamline production workflows for cell-based advanced therapies.
ABEC, a provider of engineering solutions for the biopharmaceutical industry, has announced the commercial availability of its ATB-2100 bioreactor. The system utilizes single-use technology, a growing preference in the bioprocessing sector due to its ability to reduce cross-contamination and turnaround times.
The ATB-2100 is engineered to address the specific production challenges inherent in advanced therapies, such as cell and gene products. By moving away from traditional stainless-steel fixed systems, manufacturers can utilize modular workflows that facilitate more frequent batch changes and reduced cleaning validation requirements.
The platform supports scaling processes from early-stage clinical development through to large-scale commercial output. Industry analysts note that as demand for personalized medicine increases, the adoption of standardized single-use hardware remains a critical factor for reducing capital expenditure in biopharmaceutical facilities.